Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts.

Stacchiotti, Silvia; Dürr, Hans Roland; Schaefer, Inga-Marie; Woertler, Klaus; Haas, Rick; Trama, Annalisa; Caraceni, Augusto; Bajpai, Jyoti; Baldi, Giacomo Giulio; Bernthal, Nicholas; Blay, Jean-Yves; Boye, Kjetil; Broto, Javier-Martin; Chen, Wei-Wu Tom; Dei Tos, Paolo Angelo; Desai, Jayesh; Emhofer, Stephan; Eriksson, Mikael; Gronchi, Alessandro; Gelderblom, Hans; Hardes, Jendrik; Hartmann, Wolfgang; Healey, John; Italiano, Antoine; Jones, Robin L; Kawai, Akira; Leithner, Andreas; Loong, Herbert; Mascard, Eric; Morosi, Carlo; Otten, Nadine; Palmerini, Emanuela; Patel, Shreyaskumar R; Reichardt, Peter; Rubin, Brian; Rutkowski, Piotr; Sangalli, Claudia; Schuster, Kathrin; Seddon, Beatrice M; Shkodra, Morena; Staals, Eric L; Tap, William; van de Rijn, Matt; van Langevelde, Kirsten; Vanhoenacker, Filip M M; Wagner, Andrew; Wiltink, Lisette; Stern, Sydney; Van de Sande, Van Michiel; Bauer, Sebastian     «

Stacchiotti, Silvia; Dürr, Hans Roland; Schaefer, Inga-Marie; Woertler, Klaus; Haas, Rick; Trama, Annalisa; Caraceni, Augusto; Bajpai, Jyoti; Baldi, Giacomo Giulio; Bernthal, Nicholas; Blay, Jean-Yves; Boye, Kjetil; Broto, Javier-Martin; Chen, Wei-Wu Tom; Dei Tos, Paolo Angelo; Desai, Jayesh; Emhofer, Stephan; Eriksson, Mikael; Gronchi, Alessandro; Gelderblom, Hans; Hardes, Jendrik; Hartmann, Wolfgang; Healey, John; Italiano, Antoine; Jones, Robin L; Kawai, Akira; Leithner, Andreas; Loong, Herbe...     »

Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive, mesenchymal tumor arising from the joints, bursa and tendon sheaths. TGCT comprises a nodular- and a diffuse-type, with the former exhibiting mostly indolent course and the latter a locally aggressive behavior. Although usually not life-threatening, TGCT may cause chronic pain and adversely impact function and quality of life (QoL). CSFR1 inhibitors are effective with benefit on symptoms and QoL but are not available in most countries. The degree of uncertainty in selecting the most appropriate therapy and the lack of guidelines on the clinical management of TGCT make the adoption of new treatments inconsistent across the world, with suboptimal outcomes for patients. A global consensus meeting was organized in June 2022, involving experts from several disciplines and patient representatives from SPAGN to define the best evidence-based practice for the optimal approach to TGCT and generate the recommendations presented herein.      «

Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive, mesenchymal tumor arising from the joints, bursa and tendon sheaths. TGCT comprises a nodular- and a diffuse-type, with the former exhibiting mostly indolent course and the latter a locally aggressive behavior. Although usually not life-threatening, TGCT may cause chronic pain and adversely impact function and quality of life (QoL). CSFR1 inhibitors are effective with benefit on symptoms and QoL but are not available in most co...     »